Wikipedia
CureVac
CureVac is a biopharmaceutical company headquartered in Tübingen, Germany, that develops therapies based on messenger RNA (mRNA). The main research primarily focuses on cancer immunotherapies and prophylactic vaccines against infectious diseases. Founded in 2000, CureVac currently has about 240 employees.
Since inception, CureVac had received approximately $330 million (€300 million) in equity investments. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, the Bill & Melinda Gates Foundation and the International AIDS Vaccine Initiative.